Log in

RegulatoryCNBC-TV18

Caplin Point shares decline after USFDA OAI classification

Negative-67

GreyOak summary

Caplin Point Laboratories reported that the USFDA classified its Gummidipoondi facility as 'official action indicated' following an inspection. The company stated it does not expect a material impact on financials or operations. Shares declined 2.1% to ₹2,298 despite the firm's recent 15.3% net profit growth.

What it affects

Source

Read the original at CNBC-TV18

More Caplin Point Laboratories news

All Caplin Point Laboratories news →

We use cookies

Essential cookies keep GreyOak secure and functional. Optional cookies help improve your experience and platform performance. You can update your preferences anytime.

Cookie Policy